Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.1 (
ACS
)
78,556
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The activity of four native FDHs and four engineered
FDH
variants on 93 low molecular weight arenes was used to generate
FDH
substrate activity profiles. These profiles provided insights into how substrate class, functional group substitution, electronic activation, and binding impact
FDH
activity and selectivity. The enzymes studied could halogenate a far greater range of substrates than previously recognized, but significant differences in their substrate specificity and selectivity were observed. Trends between the electronic activation of each site on a substrate and halogenation conversion at that site were established, and these data, combined with docking simulations, suggest that substrate binding can override electronic activation even on compounds differing appreciably from native substrates. These findings provide a useful framework for understanding and exploiting
FDH
reactivity for organic synthesis.
ACS
Catal 2017 Mar 03
PMID:Understanding Flavin-Dependent Halogenase Reactivity via Substrate Activity Profiling. 2898 9